April 13, 2022
Under the chairmanship of the Minister of Science and Higher Education of the Russian Federation Valery Valkov, a working group meeting was held on the development of research and development work in the field of production of medicinal and preventive drugs.
The meeting was attended by heads of scientific institutes and universities concerned with scientific development and training of workers in the fields of medicine, pharmacy, chemistry and biology. The main topic was the production of sanctioned drugs.
Russia already has a large backlog in the field of medical sciences. At the moment, there is no ban on the supply of medicines from unfriendly countries. However, preventive measures are needed to rule out possible drug shortages. Many domestic institutes have successful experience in pharmaceutical development, which has become important medical products. “In the current situation, under the conditions of sanctions pressure, confident cooperation between authorities, scientific institutions and the real sector of the economy is necessary for the rapid implementation of the results of scientific research,” said Valery Valkov.
Alexander Gabipov, Director of the Institute of Organic Biochemistry of the Russian Academy of Sciences, confirmed his readiness to immediately put the drugs on the market in case of shortage.
Our institute can develop, express, and transport virtually any genetically modified drug to a robust production site. It is necessary to collect the minimum amount of drugs of concern in terms of supply. Our industry has already perfected a lot of them. “The impotence must be eliminated,” said Alexander Gabipov.
Experts have determined that all research institutes of the Ministry of Education and Science of the Russian Federation have significant experience in full-cycle drug development, and many institutes have all the necessary elements of a bio-infrastructure that allows screening and testing of promising molecules in cell cultures, conducting preclinical and clinical studies.
Director of the Federal Scientific Center for Research and Development of Bioimmune Products on the name of M. The Chumakov Institute of the Russian Academy of Sciences, Idar Ishmukhametov, drew attention to the fact that over the past five years, the organization has produced more than six vaccines and put them into civilian circulation. The center also owns the production of the third vaccine in Russia against the infection with the Corona virus CoviVac.
“It is necessary to develop science-intensive technologies in drug production, and not to make generic drugs. Today, in partnership with doctors, we will create vaccines aimed at preventing cancer,” said Idar Ishmokhametov about the action plans.
Scientists agreed that in the current situation, in order to accelerate development, a centrally qualified agent is needed, which will set a specific task, for example, the creation of a new bacterial or antiviral agent and other drugs, and research institutes in the framework of work. From the consortia organized according to the territorial principle will undertake the development of the pharmaceutical companies.
Experts anticipate that in the medium term there will be a significant reformulation of work in the field of medicine, in the positions of both the Ministry of Health and the Ministry of Education and Science of Russia, with a move towards cell products, individual pharmaceuticals and especially in the field of oncology, rheumatology and others.
At the conclusion of the meeting, the participants came out with an initiative to create a new unified alternative program for importing medical products that could be coordinated by the Ministry of Education, the Ministry of Health and the Ministry of Industry and Trade. from Russia.